Recommendations on cutaneous and hematological manifestations of Sjögren’s disease by the Brazilian Society of Rheumatology-Reference-Cited by-同舟云学术

Recommendations on cutaneous and hematological manifestations of Sjögren’s disease by the Brazilian Society of Rheumatology

Published:2024-07-09 Issue:1 Volume:64 Page:
ISSN:2523-3106
Container-title:Advances in Rheumatology
language:en
Short-container-title:Adv Rheumatol

Author:

Pugliesi Alisson^ORCID,Egypto Danielle Christinne Soares do^ORCID,Duffles Guilherme,Cantali Diego Ustárroz^ORCID,Pasoto Sandra Gofinet^ORCID,Oliveira Fabiola Reis,Valim Valeria,Lopes Maria Lucia Lemos^ORCID,Miyamoto Samira Tatiyama,Fernandes Marilena Leal Mesquita Silvestre,Fialho Sonia Cristina de Magalhães Souza,Pinheiro Aysa César^ORCID,Santos Laura Caldas dos,Appenzeller Simone,Ribeiro Sandra Lucia Euzébio^ORCID,Libório-Kimura Tatiana Nayara,Santos Maria Carmen Lopes Ferreira Silva,Gennari Juliana D´Agostino,Pernanbuco Roberta,Capobiano Karina Gatz,Civile Vinicius Tassoni,Pinto Ana Carolina Pereira Nunes,Rocha-Filho César Ramos^ORCID,Rocha Aline Pereira da,Trevisani Virginia Fernandes Moça^ORCID

Abstract

AbstractSjogren’s disease (SjD) is an autoimmune disease that is characterized not only by the sicca symptoms it causes but also by its systemic nature, which is capable of several and not yet fully understood extraglandular manifestations. To gain a clearer understanding of these manifestations as well as a better practical approach, a panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis on the identification of epidemiologic and clinical features of the extraglandular manifestations present in ESSDAI (EULAR Sjogren´s syndrome disease activity index), followed by a voting panel with recommendations for clinical practice. This publication is complementary to others already published and covers cutaneous and hematological manifestations, with prevalence data generated by a meta-analysis of 13 clinical or laboratory manifestations and 6 clinical management recommendations.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s42358-024-00391-x.pdf

Reference81 articles.

1. Moutsopoulos HM, Chused TM, Mann DL, Klippel JH, Fauci AS, Frank MM, et al. Sjögren’s syndrome (Sicca syndrome): current issues. Ann Intern Med. 1980 Feb;92(2 Pt 1):212–26. https://doi.org/10.7326/0003-4819-92-2-212.

2. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren’s syndrome. Semin Arthritis Rheum. 2000 Apr;29(5):296–304. https://doi.org/10.1016/s0049-0172(00)80016-5.

3. Beydon M, McCoy S, Nguyen Y, Sumida T, Mariette X, Seror R. Epidemiology of Sjögren syndrome. Nat Rev Rheumatol. 2024 Mar;20(3):158–69. https://doi.org/10.1038/s41584-023-01057-6.

4. Valim V, Zandonade E, Pereira AM, de Brito Filho OH, Serrano EV, Musso C, et al. Primary Sjögren’s syndrome prevalence in a major metropolitan area in Brazil. Rev Bras Reumatol. 2013 Feb;53(1):24–34.

5. Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjögren syndrome. Nat Rev Dis Primers. Jul 2016;2:16047. https://doi.org/10.1038/nrdp.2016.47.